Aspirin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1950
- First approval year
- 1950
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Aspirin
- Molecular weight
- 180.16
- Structure (SMILES)
- CC(=O)Oc1ccccc1C(=O)O
- 8 hour bayer
- 8-hour bayer
- acetosalic acid
- Acetosalic acid
- acetylsalic acid
- Acetylsalic acid
- alka rapid
- Alka rapid
- anadin all night
- Anadin all night
- angettes 75
- Angettes 75
- aspirin
- Aspirin
- Aspirin component of -pc
- aspirin component of aggrenox
- Aspirin component of aggrenox
- aspirin component of axotal
- Aspirin component of axotal
- aspirin component of azdone
- Aspirin component of azdone
- aspirin component of carisoprodol compound
- Aspirin component of carisoprodol compound
- aspirin component of clopidogrel acetylsalicylic acid
- Aspirin component of clopidogrel/acetylsalicylic acid
And 105 more, listed on the interactive page.
- 150 mg acetylsalicylic acid
- 325 mg ASA
- 75 mg acetylsalicylic acid
- acetyl salicylate
- Acetyl salicylate
- Acetyl Salicylate
- Acetyl salicylic acid (ASA)
- Acetyl Salicylic Acid (ASA)
- acetylsalicyclic acid (ASA)
- acetylsalicylic acid
- Acetylsalicylic acid
- Acetylsalicylic Acid
- acetylsalicylic acid (ASA)
- Acetylsalicylic acid (ASA)
- Acetylsalicylic Acid (ASA)
- acetylsalicylic acid (ASA) 81mg
- acetylsalicylic acid (ASA) 81mg Oral Tablet
- acetylsalicylic acid (ASA) therapy
- acetylsalicylic acid (below or equal to) 250 mg
- Acetylsalicylic acid (who-ip)
- ACETYLSALICYLIC ACID [EMA EPAR]
- ACETYLSALICYLIC ACID [EP MONOGRAPH]
- ACETYLSALICYLIC ACID [GREEN BOOK]
- Acetylsalicylic acid [WHO-DD]
- Acetylsalicylic acid 100 MG
And 129 more, listed on the interactive page.
- CAS registry numbers
- 50-78-2
- ChEMBL ID
- CHEMBL25
- InChIKey
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N
- PubChem compound IDs
- 2244
- RxNorm IDs (RxCUI)
- 1191
- FDA ingredient codes (UNII)
- R16CO5Y76E
- A01AD05
- B01AC06
- N02BA01
- N02BA51
- N02BA71
Sources for recorded values
- Applicant
- HALEON US HOLDINGS
- Approval date
- 14 Jan 1998
- Application number
- NDA020802
- Patents
- 15
- Designations
- 2
- Earliest recorded loss of exclusivity
- 13 Mar 2033
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- aspirin
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- ASIC3
- Gene symbol
- ASIC3
- Protein identifier
- Q9UHC3
- Median affinity
- 4
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- COX-1
- Gene symbol
- PTGS1
- Protein identifier
- P23219
- Median affinity
- 3.25
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- COX-2
- Gene symbol
- PTGS2
- Protein identifier
- P35354
- Median affinity
- 5.62
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Cyclooxygenase inhibitor
- Action type
- Inhibitor
- Target
- Cyclooxygenase
- Protein identifier
- P23219
- Mechanism
- Cyclooxygenase inhibitor
- Action type
- Inhibitor
- Target
- Cyclooxygenase
- Protein identifier
- P35354
Open Targets mechanisms
- Mechanism
- Cyclooxygenase inhibitor
- Action type
- Inhibitor
- Target
- Cyclooxygenase
- Action type
- Blocker
- Gene symbol
- ASIC3
- Protein identifier
- Q9UHC3
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Action type
- Inhibitor
- Gene symbol
- PTGS1
- Protein identifier
- P23219
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- PTGS2
- Protein identifier
- P35354
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Metabolic Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000195
- Subject identifier
- D024821
- Condition
- Aortic Valve Stenosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000266
- Subject identifier
- D001024
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Barrett Esophagus
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000280
- Subject identifier
- D001471
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Thrombocythemia, Essential
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000479
- Subject identifier
- D013920
- Condition
- Fetal Growth Retardation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000495
- Subject identifier
- D005317
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Cardiomyopathy, Hypertrophic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000538
- Subject identifier
- D002312
- Condition
- Infertility
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000545
- Subject identifier
- D007246
- Condition
- Wounds and Injuries
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Ischemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000556
- Subject identifier
- D007511
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Myocardial Infarction
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Periodontitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000649
- Subject identifier
- D010518
- Condition
- Pre-Eclampsia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000668
- Subject identifier
- D011225
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
And 142 more, listed on the interactive page.
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000266
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000275
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000342
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000479
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000495
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000538
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000556
- Condition identifier
- EFO_0000556
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000612
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000649
- Condition identifier
- EFO_0000668
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000684
- Highest recorded phase
- 2
And 295 more, listed on the interactive page.
- Event
- anaemia
- Reports
- 2,225
- Reporting signal score
- 1,634.47
- Event
- angioedema
- Reports
- 718
- Reporting signal score
- 558.352
- Event
- aspirin-exacerbated respiratory disease
- Reports
- 254
- Reporting signal score
- 897.759
- Event
- cerebral haemorrhage
- Reports
- 502
- Reporting signal score
- 672.864
- Event
- drug hypersensitivity
- Reports
- 1,836
- Reporting signal score
- 909.021
- Event
- duodenal ulcer
- Reports
- 363
- Reporting signal score
- 652.822
- Event
- epistaxis
- Reports
- 857
- Reporting signal score
- 794.32
- Event
- faeces discoloured
- Reports
- 384
- Reporting signal score
- 524.711
- Event
- gastric haemorrhage
- Reports
- 596
- Reporting signal score
- 1,254.97
- Event
- gastric ulcer
- Reports
- 657
- Reporting signal score
- 1,192.75
- Event
- gastric ulcer haemorrhage
- Reports
- 233
- Reporting signal score
- 444.313
- Event
- gastritis erosive
- Reports
- 239
- Reporting signal score
- 462.738
- Event
- gastrointestinal haemorrhage
- Reports
- 3,187
- Reporting signal score
- 5,991.53
- Event
- haematemesis
- Reports
- 722
- Reporting signal score
- 1,135.65
- Event
- haematochezia
- Reports
- 896
- Reporting signal score
- 1,214.87
- Event
- haematoma
- Reports
- 571
- Reporting signal score
- 697.329
- Event
- haematuria
- Reports
- 686
- Reporting signal score
- 766.702
- Event
- haemoglobin decreased
- Reports
- 1,223
- Reporting signal score
- 901.739
- Event
- haemorrhage
- Reports
- 1,124
- Reporting signal score
- 1,117.18
- Event
- haemorrhage intracranial
- Reports
- 444
- Reporting signal score
- 731.655
- Event
- haemorrhagic anaemia
- Reports
- 233
- Reporting signal score
- 460.032
- Event
- international normalised ratio increased
- Reports
- 518
- Reporting signal score
- 444.746
- Event
- labelled drug-drug interaction medication error
- Reports
- 622
- Reporting signal score
- 1,424.98
- Event
- lower gastrointestinal haemorrhage
- Reports
- 351
- Reporting signal score
- 712.139
- Event
- melaena
- Reports
- 1,171
- Reporting signal score
- 2,273.94
And 4 more, listed on the interactive page.
- NCT00000151
- NCT00000152
- NCT00000161
- NCT00000157
- NCT00000469
- NCT00000479
- NCT00000496
- NCT00000527
- NCT00000500
- NCT00000510
- NCT00425074
- NCT00501059
- NCT00935506
- NCT01057537
- NCT01082874
- NCT01245608
- NCT01271985
- NCT01313702
- NCT02370680
- NCT03459560
- NCT04588727
- NCT04792723
- NCT05525156
- NCT05633810
- NCT02677545
And 347 more, listed on the interactive page.
- Dose
- 4-8 tablets
- Route
- Oral
- How often
- Every 4 hours
Conditions of use
- Do not exceed 48 tablets in 24 hours
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 63.6
- Calculated partition coefficient (ALogP)
- 1.31
- Calculated partition coefficient (XLogP)
- 1.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 13
- Molecular formula
- C9H8O4
- Monoisotopic mass
- 180.04225873
- Natural product
- Yes
- 0527-1552
- 0781-2270
- 0904-7056
- 16714-964
- 42291-116
- 42571-274
- 42806-061
- 43598-339
- 49884-007
- 50991-999
- 51991-074
- 61825-302
- 61825-305
- 65162-596
- 68462-405
- 69367-416
- 71993-304
- 71993-307
- 63629-2952
- 63629-5045
- 69238-1993
- 79739-6094
- 79739-7192
- Recorded assays
- 7,253
- Active assays
- 125
- Confirmatory
- Other
- Anti-Inflammatory Agents, Non-Steroidal
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
Distribution coefficient (LogD)
- Median
- -2.57
- Mean
- -2.31667
- Minimum
- -2.57
- Maximum
- -1.81
- Unit
- unitless
- Assays
- 3
- Standard deviation
- 0.438786
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Solubility
- Median
- 39,770
- Mean
- 31,852.5
- Minimum
- 3,300
- Maximum
- 44,570
- Unit
- ug/mL
- Assays
- 4
- Standard deviation
- 19,296.3
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 79
- Mean
- 82.3333
- Minimum
- 68
- Maximum
- 100
- Unit
- %
- Assays
- 3
- Standard deviation
- 16.2583
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 84
- Mean
- 75.3333
- Minimum
- 52
- Maximum
- 90
- Unit
- %
- Assays
- 3
- Standard deviation
- 20.4287
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (1,128)
- "Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up
- [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
- 1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
- 162 mg of Aspirin for Prevention of Preeclampsia
- 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
- 3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
- 30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers
- A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin
- A Clinical Trial of Antiplatelets in Psoriasis
- A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
- A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
- A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain
- A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
- A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
- A Different Approach to Preventing Thrombosis
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)
- A Healthy Female and Male Volunteers Aspirin Study
- A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
- A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin
- A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
Approved for (9)
- Acute myocardial infarction
- Arthritic joint disease
- Common cold
- Coronary artery disorder
- Dysmenorrhea
- Migraine disorder
- Myocardial infarction
- Stroke disorder
- Thrombotic disease
In development for (134)
- Acquired polycythemia vera Phase 3
- Acute chest syndrome Phase 3
- Acute coronary syndrome Phase 3
- Acute lung injury Phase 2
- Acute respiratory distress syndrome Phase 2
- Adenomyosis Early phase 1
- Age-related macular degeneration Phase 3
- Alcoholic liver disease Early phase 1
- Aortic valve stenosis Phase 3
- Asthma Phase 3
- Atherosclerosis Phase 3
- Atrial fibrillation Phase 3
- Autoimmune thrombocytopenic purpura Phase 2
- Barrett esophagus Phase 2
- Bipolar disorder Phase 3
- Blindness (disorder) Phase 3
- Blood coagulation disease Phase 2
- Bone fracture Early phase 1
- Brain aneurysm Phase 3
- Brain infarction Phase 3
Other linked conditions (13)
- Anterior ischemic optic neuropathy
- Atopic eczema
- Carotid artery disorder
- Cerebral amyloid angiopathy
- Chronic pancreatitis
- Colorectal neoplasm
- Drug dependence
- Extrahepatic cholestasis
- Frozen shoulder
- Intermediate coronary syndrome
- Moyamoya disease
- Patent foramen ovale
- Thyroid gland disorder